Bronchodilator Drugs - Africa

Africa

In Africa, the revenue in the Bronchodilator Drugs market is projected to reach €296.50m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 3.93%, resulting in a market volume of €359.50m by 2029.
When compared globally, United States is anticipated to generate the highest revenue of €15,910.00m in 2024.
In Africa, the demand for bronchodilator drugs is on the rise due to the high prevalence of respiratory diseases and the increasing awareness about managing respiratory health.

Key regions: United States, Europe, Brazil, Japan, United Kingdom

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

Bronchodilator drugs are becoming increasingly popular in Africa due to the high prevalence of respiratory diseases in the region. With a growing population and increasing urbanization, the demand for these drugs is expected to continue to rise in the coming years.

Customer preferences: In Africa, there is a preference for affordable and easily accessible healthcare solutions. Many individuals in the region rely on public healthcare facilities, which may not always have the necessary drugs in stock. As a result, there is a growing demand for over-the-counter bronchodilator drugs that can be purchased without a prescription. Additionally, there is a preference for generic drugs over branded ones due to their lower cost.

Trends in the market: In countries such as Nigeria, South Africa, and Egypt, there has been a significant increase in the prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). This has led to a rise in demand for bronchodilator drugs, which are used to treat these conditions. Furthermore, there has been a trend towards the development of combination drugs, which contain multiple active ingredients and can provide more comprehensive treatment for respiratory diseases.

Local special circumstances: In many African countries, there is a lack of access to quality healthcare facilities and trained medical professionals. This has led to a reliance on self-medication and over-the-counter drugs. Additionally, there is a lack of regulation in some countries, which can lead to the sale of counterfeit drugs. This has created a need for increased regulation and quality control in the pharmaceutical industry.

Underlying macroeconomic factors: The African pharmaceutical market is expected to continue to grow in the coming years due to factors such as population growth, urbanization, and increasing healthcare spending. However, there are challenges such as inadequate infrastructure, political instability, and a lack of skilled labor that may hinder the growth of the industry. Additionally, the COVID-19 pandemic has had a significant impact on the pharmaceutical industry in Africa, with disruptions to supply chains and decreased demand for non-essential drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.